Patent Failed to Enable Dosage Claims
WYETH LLC V. ASTRAZENECA PHARMA. LP Before Lourie, Linn, and Hughes. Appeal from District Court for the District of Delaware. Summary: Patent claims were not enabled because the specification failed...
Prosecution Statements Can Create Substantial Questions of Noninfringement at the Preliminary Injunction Stage
Ridge Corp., et al. v. Kirk NationaLease Co., et al. Before Dyk, Mayer, and Taranto. Appeal from the United States District Court for the Southern District of Ohio. Summary: A...
Preliminary Injunction Vacated Due to Claim Construction Errors
Socket Solutions, LLC v. Import Global, LLC Before Moore, Prost, and Seeborg. Appeal from the U.S. District Court for the Southern District of Florida. Summary: A preliminary injunction cannot stand...
Avoiding Greenwashing Claims: Litigation Risks and Regulatory Guidance
Key Takeaway: Energy companies that market their technologies as environmentally friendly should ensure the claims are accurate and consistent with regulatory guidance. Innovation in the energy industry is often driven...
Federal Circuit Sheds Light on “Skilled Searcher” Standard for IPR Estoppel
IRONBURG INVENTIONS LTD. v. VALVE CORPORATION Before Chen, Hughes, and Stark. Appeal from the United States District Court for the Western District of Washington. Summary: The Federal Circuit reversed and...
U.S. Patent Claim Strategies for In-Space Repair and Orbital Assembly Technologies
Key Takeaways: Given the territorial limitations of U.S. Patent Claims, patenting technology for in-space repair and assembly of orbital technology can be challenging. The following blog post discusses strategies for...
Federal Circuit Review | July 2026
July Federal Circuit Newsletter (Japanese) July Federal Circuit Newsletter (Chinese) PTAB May Revisit Issues Left Unresolved by Prior Appeal In Intellectual Pixels Limited v. Sony Interactive Entertainment LLC, Appeal...
FDA Approves First mRNA-Based Flu Vaccine, Highlighting Growing Patent Value in mRNA Platforms
Key Takeaway: The FDA’s approval of mFLUSIVA may indicate increased commercial and strategic value of mRNA vaccine patents. On August 5, 2026, Moderna announced that the U.S. Food and Drug...
Energy Update | July 2026
Solar Boom Highlights Importance of Robust IP Strategy Michael E. Salamy Solar has reached a historic milestone, surpassing coal in U.S. electricity generation as rising demand and record investment accelerate...
